5 Pharmaceutical Stocks to Buy Now

The grades of five pharmaceutical stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.

This week, NuPathe Inc. (PATH) is showing significant improvement as the company’s rating hops from a C (“hold”) to a B (“buy”). NuPathe develops pharmaceutical products used for the treatment and management of neurological and psychiatric diseases. In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, PATH also gets A’s. For more information, get Portfolio Grader’s complete analysis of PATH stock.

Supernus Pharmaceuticals, Inc. (SUPN) boosts its rating from a C to a B this week. Supernus Pharmaceuticals is a specialty pharmaceutical company that develops and markets proprietary drugs for the treatment of central nervous system diseases and disorders. For more information, get Portfolio Grader’s complete analysis of SUPN stock.

Salix Pharmaceuticals, Ltd.’s (SLXP) ratings are looking better this week, moving up to a B from last week’s C. Salix Pharmaceuticals acquires, develops and commercializes prescription drugs used to treat gastrointestinal diseases. For more information, get Portfolio Grader’s complete analysis of SLXP stock.

Watson Pharmaceuticals (WPI) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.

This is a strong week for Akorn, Inc. (AKRX). The company’s rating climbs to A from the previous week’s B. Akorn engages in the manufacture and marketing of diagnostic and therapeutic ophthalmic pharmaceuticals products, niche hospital drugs, and injectable pharmaceuticals in the United States and internationally. For more information, get Portfolio Grader’s complete analysis of AKRX stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2015/01/5-pharmaceutical-stocks-to-buy-now-path-supn-slxp/.

©2020 InvestorPlace Media, LLC